Spyre Therapeutics (SYRE) Stock Price, News & Analysis

+0.89 (+2.75%)
(As of 04/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
261,719 shs
Average Volume
462,261 shs
Market Capitalization
$1.20 billion
P/E Ratio
Dividend Yield
Price Target

Spyre Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
17.7% Upside
$39.20 Price Target
Short Interest
9.36% of Float Sold Short
Dividend Strength
News Sentiment
0.27mentions of Spyre Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($2.36) to ($2.52) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.45 out of 5 stars

Medical Sector

868th out of 910 stocks

Pharmaceutical Preparations Industry

407th out of 426 stocks

SYRE stock logo

About Spyre Therapeutics Stock (NASDAQ:SYRE)

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

SYRE Stock Price History

SYRE Stock News Headlines

Spyre Therapeutics Inc (SYRE)
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
TD Cowen Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)
Spyre Therapeutics Enhances Protection for Executives and Board
See More Headlines
Receive SYRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
($0.22) per share


Free Float
Market Cap
$1.20 billion
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Cameron Turtle DPHIL (Age 34)
    Ph.D., CEO & Director
    Comp: $674.17k
  • Mr. Scott L. Burrows (Age 47)
    Chief Financial Officer
    Comp: $331.81k
  • Ms. Heidy Abreu King-Jones J.D. (Age 41)
    L.L.M., Chief Legal Officer & Corporate Secretary
    Comp: $568.87k
  • Dr. Janet Gunzner-Toste M.B.A.
    Ph.D., Senior Vice President of Operations
  • Brian Connolly
    Chief Technical Officer
  • Mr. Eric McIntyre
    Vice President of Finance & Investor Relations
  • Mr. James Myers
    Vice President of Quality & Compliance
  • Dr. Kelly Boothe Ph.D.
    Senior Director of Corporate Communications & Investor Relations
  • Dr. Justin LaFountaine Ph.D.
    Senior Vice President of Corporate Development
  • Ms. Melissa Cooper
    Senior Vice President of People

SYRE Stock Analysis - Frequently Asked Questions

Should I buy or sell Spyre Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spyre Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SYRE shares.
View SYRE analyst ratings
or view top-rated stocks.

What is Spyre Therapeutics' stock price target for 2024?

7 brokerages have issued twelve-month target prices for Spyre Therapeutics' stock. Their SYRE share price targets range from $31.00 to $54.00. On average, they expect the company's share price to reach $39.20 in the next year. This suggests a possible upside of 17.7% from the stock's current price.
View analysts price targets for SYRE
or view top-rated stocks among Wall Street analysts.

How have SYRE shares performed in 2024?

Spyre Therapeutics' stock was trading at $21.52 at the beginning of 2024. Since then, SYRE shares have increased by 54.7% and is now trading at $33.2950.
View the best growth stocks for 2024 here

When is Spyre Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SYRE earnings forecast

How were Spyre Therapeutics' earnings last quarter?

Spyre Therapeutics, Inc. (NASDAQ:SYRE) posted its earnings results on Thursday, February, 29th. The company reported ($2.28) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $1.80.

What ETFs hold Spyre Therapeutics' stock?

ETFs with the largest weight of Spyre Therapeutics (NASDAQ:SYRE) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

How do I buy shares of Spyre Therapeutics?

Shares of SYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SYRE) was last updated on 4/22/2024 by Staff

From Our Partners